Pediatric Hydrops Fetalis

  • Author: Ashraf H Hamdan, MD, MBBCh, MSc, MRCP, FAAP; Chief Editor: Ted Rosenkrantz, MD  more...
Updated: Jan 09, 2014


Hydrops fetalis (fetal hydrops) is a serious fetal condition defined as abnormal accumulation of fluid in 2 or more fetal compartments, including ascites, pleural effusion, pericardial effusion, and skin edema. In some patients, it may also be associated with polyhydramnios and placental edema. Hydrops is usually first recognized by ultrasound examination during the first or second trimester of gestation. Significant fluid collections are easily detected, but fluid accumulation may also be limited and thus escape routine ultrasound detection.

Hydrops fetalis has been a well-recognized fetal and neonatal condition throughout history. Until the latter half of the 20th century, it was believed to be due to Rhesus (Rh) blood group isoimmunization of the fetus. More recent recognition of factors other than isoimmune hemolytic disease that can cause or be associated with fetal hydrops led to the use of the term nonimmune hydrops to identify those cases in which the fetal disorder was caused by factors other than isoimmunization.

In the 1970s, the major cause of immune hydrops (ie, Rh D antigen) was conquered with the use of immunoglobulin (Ig) prophylaxis in at-risk mothers. Before routine immunization of Rh-negative mothers, most cases of hydrops were due to erythroblastosis from Rh alloimmunization. With the introduction of widespread immunoprophylaxis for red blood cell alloimmunization and the use of in utero transfusions for immune hydrops therapy, nonimmune causes have become responsible for at least 85% of all cases of fetal hydrops. Nevertheless, in developing countries, the incidence of immune fetal hydrops is still high.

For patient education resources, see the Heart Center, as well as Supraventricular Tachycardia.



Several hypotheses regarding the pathophysiologic events that lead to fetal hydrops have been suggested. The basic mechanism for the formation of fetal hydrops is an imbalance of interstitial fluid production and the lymphatic return. Fluid accumulation in the fetus can result from congestive heart failure, obstructed lymphatic flow, or decreased plasma osmotic pressure. The fetus is particularly susceptible to interstitial fluid accumulation because of its greater capillary permeability, compliant interstitial compartments, and vulnerability to venous pressure on lymphatic return.

Compensatory mechanisms for maintaining homeostasis during hypoxia that results from underlying disease include increased efficiency of oxygen extraction, redistribution of blood flow to the brain, heart, and adrenals, thus causing renal tubular damage, volume augmentation to enhance cardiac output, and marked activation of the renin-angiotensin system. Unfortunately, these mechanisms increase venous pressure and ultimately produce interstitial fluid accumulation and characteristic hydropic changes in the fetus. Increased venous pressure and contributes to edema and effusion by increasing the capillary hydrostatic pressure and decreasing the lymphatic return. Impaired renal function causes oliguria or anuria and subsequently hydrops.[1]

Furthermore, the hepatic synthesis of albumin may be impaired because of decreased hepatic perfusion and increased extramedullary hematopoiesis. Because albumin acts as the predominant oncotically active plasma protein, hypoalbuminemia increases transcapillary fluid movement at times of circulatory compromise.

Hydrops has been produced in the ovine fetus by anemia, tachyarrhythmia, occlusion of lymphatic drainage, and obstruction of cardiac venous return. Hypoproteinemia and hypoalbuminemia are common in human hydrops, and reduced intravascular oncotic pressure has been speculated to be a primary cause for the disorder. However, in the sheep model, a 41% reduction in total serum protein accompanied by a 44% decline in colloid osmotic pressure failed to produce fetal hydrops. Furthermore, a study in humans showed that, despite a significant negative correlation between the fetal serum albumin level and the degree of fetal hydrops, most fetuses with hydrops had albumin levels within the reference range.[2] These results suggest that hypoalbuminemia is unlikely to cause the primary onset of hydrops.

A closer look at the animal studies provides the clues necessary to understand the pathophysiology of hydrops. In one study, profound anemia was induced in fetal sheep; the hydrops that resulted was unrelated to hematocrit levels, blood gas levels, acid-base balance, plasma proteins, colloid oncotic pressure, or aortic pressure.[3] A difference was found in central venous pressure (CVP), which was much higher in persons with hydrops. The hematocrit level was reduced by 45% in a study of particular notation; however, CVP was maintained unchanged, and no fetus developed hydrops under these conditions.

Induced fetal tachyarrhythmia has led to fetal hydrops in several studies. Key to the development of fetal hydrops in these studies was an elevation in CVP; the anemia was only of indirect importance. CVP was markedly elevated, with a range of 25-31 mm Hg in one study. In other reports, hydrops induced by sustained fetal tachycardia was unrelated to blood gases, plasma protein, or albumin turnover; however, a 75-100% increase in CVP was observed in the fetuses that developed hydrops.

Excision of major lymphatic ducts produces fetal hydrops in the sheep model. A related study demonstrates an exquisite, linear, inverse relationship between lymphatic outflow pressure and CVP; a rise in CVP of 1 mm Hg reduces lymph flow 13%, and flow stops at a CVP of 12 mm Hg. These results are confirmed by other observations of linear decline in lymph flow when CVP exceeds 5 mm Hg and a cessation of flow at CVPs greater than 18 mm Hg.

Also of note is a computer simulation model in which cardiovascular and fluid electrolyte disturbances (eg, severe anemia, lymphatic obstruction, excess fluid and electrolyte loads, elevation in angiotensin levels) and compensating homeostatic mechanisms have been examined. This model demonstrated that "...fetal cardiac failure constituted the strongest stimulus for the formation of fetal edema...",[4] thus further substantiating the pivotal role of CVP in the development of fetal hydrops.

Many other physiologic disturbances are associated with human fetal hydrops. Elevations in aldosterone, renin, norepinephrine, and angiotensin I levels are likely to be secondary consequences. Although infusion of angiotensin I led to fetal hydrops in nephrectomized sheep, the 4-fold rise in CVP was probably the primary cause of the hydrops. The meaning of increased levels of coenzyme Q10, placental vascular endothelial growth factor, and endothelin and decreased cytokine interleukin-3 levels is unclear at this time.

However, of particular interest is the 3-fold to 5-fold increase in atrial natriuretic peptide (ANP) that accompanies both human fetal hydrops (with cardiac anomaly or isoimmunization) and ovine hydrops (induced by obstruction of venous return, sustained tachycardia, or induced anemia). A return of ANP levels to normal parallels the resolution of hydrops. These observations and the observations that vascular permeation of albumin is enhanced and cardiovascular and renal homeostatic adaptations are influenced by this peptide suggest an important role for ANP in fetal hydrops.

Evidence of low fetal plasma levels of cyclic guanosine monophosphate suggests that reduced nitric oxide production due to injury of fetal vascular endothelial cells may be involved in the development of fetal hydrops. This isolated observation requires confirmation and further study.

Despite numerous case reports, decades of clinical experience, and several research studies regarding the etiology and pathogenesis of hydrops, many questions still remain. Currently, which fetal neural and hormonal mechanisms induce and maintain the redistribution of blood flow, and which mechanisms allow metabolic disorders to cause hydrops, are almost completely unknown.[1]




United States

The precise incidence of hydrops fetalis is difficult to elucidate, because many cases are not detected prior to intrauterine fetal death and some cases may resolve spontaneously in utero. The best estimate for how common hydrops fetalis is in the United States is approximately 1 in 600 to 1 in 4000 pregnancies. The incidence of immune hydrops has significantly decreased with the wide use of passive immunization using Rh immunoglobulin for Rh-negative mothers at 28 weeks' gestation (following suspected fetomaternal hemorrhage) and postpartum (following the delivery of an Rh-positive infant). The efficacy of this program has been demonstrated by a decline in the incidence of Rh hemolytic disease of the fetus or newborn, from 65 in 10,000 births in the United States in 1960 to 10.6 in 10,000 births in 1990.


Hydrops fetalis is much more common in Southeast Asia. The best figures come from Thailand, where the expected frequency of hydrops, from homozygous alpha-thalassemia or Bart hydrops alone, is 1 in 500 to 1 in 1500 pregnancies.[5] Accurate figures from the Mediterranean region are not available; however, the commonness of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and of defects in alpha-chain hemoglobin production in several populations from this region lead to the suspicion that the incidence of hydrops in that region is much higher than it is in the United States.



Fetal hydrops carries a poor prognosis. The growing number of recognized etiologies requires a comprehensive and systematic search for causes, in particular for treatable or recurrent conditions.[6] Several diseases can be treated in utero with potential good results.

Hydrops fetalis remains a complex condition with high mortality and morbidity. The prognosis partly depends on the underlying disease; with aggressive postnatal care, the survival rate is increased in selected cases.

The outcome of hydrops fetalis depends on gestational age at birth and serum albumin level. One study suggested that hydrops resulting from lymphatic malformations has a favorable outcome.[7] Preterm birth at less than 34 weeks' gestation and a serum albumin concentration level of less than 2 g/dL are poor prognostic factors for survival. A more recent study found that there is strong association between gestational age, the presence of 2 or more serous cavity effusions, and poor outcome in infants with hydrops fetalis.[8]


The diagnosis and management of fetal hydrops have improved in recent years with advances in prenatal diagnostic and therapeutic interventions together with the advances in neonatal intensive care. However, fetal hydrops is still associated with a high mortality rate.

Estimates of mortality vary widely, from nearly zero to virtually 100%. Most case series report 60-90% mortality, although some improvements are notable in more recent reports. Many causes for these variations are recognized, not the least of which include the sophistication of diagnostic methods used and the complexity and costs of treatment.

However, the most important single factor is the cause of the hydrops. A significant proportion of these cases are caused or accompanied by multiple and complex congenital malformations of genetic and/or chromosomal origin, which by themselves are fatal at an early age. Many other causes are accompanied by masses or fluid accumulations, which compress the developing fetal lung and preclude its normal development. Thus, the presence or absence and potential prevention of pulmonary hypoplasia are of crucial importance.

Another highly important factor is the very premature delivery of most babies with hydrops consequent to conditions that distend the uterus and provoke early labor or to therapeutic interventions (eg, fetal thoracentesis, paracentesis, complex fetal surgical procedures).

One study showed that mortality rate was highest among neonates with congenital anomalies (57.7%) and lowest among neonates with congenital chylothorax (5.9%).[9] Infants who died were more likely to be more premature, were sicker after birth, with lower 5-minute Apgar scores, and needed higher levels of support during the first day after birth.


Ethnic influences are related almost entirely to cause. Selected examples include the importance of genetic variations in the alpha-chain structure of hemoglobin in Asian and Mediterranean populations in addition to the more serious nature of the hemolytic disease in the African American fetus affected by maternal ABO-factor isoimmunization.


Sex influences in incidence or outcome of hydrops fetalis are largely related to the cause of the condition. A significant proportion of hydrops is caused by or associated with chromosomal abnormalities or syndromes. Many of these are X-linked disorders.

Because most individuals with hydrops fetalis are delivered quite prematurely, and because fetal pulmonary maturation takes place earlier in female than in male fetuses, male preterm infants are at greater risk for the pulmonary complications of very preterm delivery. They are also at greater risk for infections (nosocomial or otherwise), which are quite common in the very preterm infant. A striking example of greater male risk is the nearly 13-fold increase in the odds ratio for development of hydrops in the male fetus with Rh D hemolytic disease. Although a single precise risk figure is not available for the heterogenous collection of cases that comprise hydrops fetalis, male fetuses appear to have greater risk for occurrence, morbidity, and mortality.

Contributor Information and Disclosures

Ashraf H Hamdan, MD, MBBCh, MSc, MRCP, FAAP Adjunct Associate Clinical Professor of Pediatrics, Vanderbilt University Medical Center; Neonatologist, Pediatrix Medical Group of Nashville

Ashraf H Hamdan, MD, MBBCh, MSc, MRCP, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Arun K Pramanik, MD, MBBS Professor of Pediatrics, Louisiana State University Health Sciences Center

Arun K Pramanik, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, National Perinatal Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, Eastern Society for Pediatric Research, American Medical Association, Connecticut State Medical Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

David N Sheftel, MD, MD Assistant Professor of Pediatrics, Chicago Medical School at Rosalind Franklin University of Medicine and Science

David N Sheftel, MD, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics

Disclosure: Nothing to disclose.


The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous author, George Cassady, MD, to the development and writing of this article.

  1. Bellini C, Hennekam RC. Non-immune hydrops fetalis: a short review of etiology and pathophysiology. Am J Med Genet A. 2012 Mar. 158A(3):597-605. [Medline].

  2. Pasman SA, Meerman RH, Vandenbussche FP, Oepkes D. Hypoalbuminemia: a cause of fetal hydrops?. Am J Obstet Gynecol. 2006 Apr. 194(4):972-5. [Medline].

  3. Blair DK, Vander Straten MC, Gest AL. Hydrops in fetal sheep from rapid induction of anemia. Pediatr Res. 1994 May. 35(5):560-4. [Medline].

  4. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997 Mar 15. 29(4):709-15. [Medline].

  5. Kitsirisakul B, Steger HF, Sanguansermsri T. Frequency of alpha-thalassemia-1 of the Southeast Asian-type among pregnant women in northern Thailand determined by PCR technique. Southeast Asian J Trop Med Public Health. 1996 Jun. 27(2):362-3. [Medline].

  6. Desilets V, Audibert F. Investigation and management of non-immune fetal hydrops. J Obstet Gynaecol Can. 2013 Oct. 35(10):923-38. [Medline].

  7. Huang HR, Tsay PK, Chiang MC, Lien R, Chou YH. Prognostic factors and clinical features in liveborn neonates with hydrops fetalis. Am J Perinatol. 2007 Jan. 24(1):33-8. [Medline].

  8. Takci S, Gharibzadeh M, Yurdakok M, Ozyuncu O, Korkmaz A, Akcoren Z, et al. Etiology and Outcome of Hydrops Fetalis: Report of 62 Cases. Pediatr Neonatol. 2013 Oct 1. [Medline].

  9. Abrams ME, Meredith KS, Kinnard P, Clark RH. Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death. Pediatrics. 2007 Jul. 120(1):84-9. [Medline].

  10. Lin SM, Wang CH, Zhu XY, Li SL, Lin SM, Fang Q. [Clinical study on 156 cases with hydrops fetalis]. Zhonghua Fu Chan Ke Za Zhi. 2011 Dec. 46(12):905-10. [Medline].

  11. Bellini C, Hennekam RC, Fulcheri E, Rutigliani M, Morcaldi G, Boccardo F. Etiology of nonimmune hydrops fetalis: A systematic review. Am J Med Genet A. 2009 Mar 30. [Medline].

  12. Bellini C, Hennekam RC. Non-immune hydrops fetalis: a short review of etiology and pathophysiology. Am J Med Genet A. 2012 Mar. 158A(3):597-605. [Medline].

  13. Bowman J, Harman C, Manning F, et al. Intravenous drug abuse causes Rh immunization. Vox Sang. 1991. 61(2):96-8. [Medline].

  14. Nakayama R, Yamada D, Steinmiller V, Hsia E, Hale RW. Hydrops fetalis secondary to Bart hemoglobinopathy. Obstet Gynecol. 1986 Feb. 67(2):176-80. [Medline].

  15. Joshi DD, Nickerson HJ, McManus MJ. Hydrops fetalis caused by homozygous alpha-thalassemia and Rh antigen alloimmunization: report of a survivor and literature review. Clin Med Res. 2004 Nov. 2(4):228-32. [Medline].

  16. Pfister KM, Schleiss MR, Reed RC, George TN. Non-immune hydrops fetalis caused by herpes simplex virus type 2 in the setting of recurrent maternal infection. J Perinatol. 2013 Oct. 33(10):817-20. [Medline].

  17. Bachmaier N, Fusch C, Stenger RD, et al. Nonimmune hydrops fetalis due to enterovirus infection. Eur J Obstet Gynecol Reprod Biol. 2009 Jan. 142(1):83-4. [Medline].

  18. Meritet JF, Krivine A, Lewin F, Poissonnier MH, Poizat R, Loget P. A case of congenital lymphocytic choriomeningitis virus (LCMV) infection revealed by hydrops fetalis. Prenat Diagn. 2009 Feb 27. [Medline].

  19. Essary LR, Vnencak-Jones CL, Manning SS, et al. Frequency of parvovirus B19 infection in nonimmune hydrops fetalis and utility of three diagnostic methods. Hum Pathol. 1998 Jul. 29(7):696-701. [Medline].

  20. Kiyota A, Tsukimori K, Yumoto Y, et al. Spontaneous resolution of cystic hygroma and hydrops in a fetus with Noonan's syndrome. Fetal Diagn Ther. 2008. 24(4):499-502. [Medline].

  21. Iskender C, Tarim E, Yalcinkaya C. Prenatal diagnosis of right diaphragmatic eventration associated with fetal hydrops. J Obstet Gynaecol Res. 2012 May. 38(5):858-62. [Medline].

  22. Lee FL, Said N, Grikscheit TC, Shin CE, Llanes A, Chmait RH. Treatment of Congenital Pulmonary Airway Malformation Induced Hydrops Fetalis via Percutaneous Sclerotherapy. Fetal Diagn Ther. 2012 Feb 18. [Medline].

  23. Stocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum Pathol. 1977 Mar. 8(2):155-71. [Medline].

  24. Matsubara S, Ohmaru T, Ohkuchi A, Arai F, Kuwata T, Usui R. Mirror syndrome associated with hydropic acardius in triplet pregnancy. Fetal Diagn Ther. 2008. 24(4):429-33. [Medline].

  25. Liley AW. Liquor amnii analysis in the management of the pregnancy complicated by Rhesus sensitization. Am J Obstet Gynecol. 1961. 82(6):1359-1370.

  26. [Guideline] Leduc L, Farine D, Armson BA, et al. Stillbirth and bereavement: guidelines for stillbirth investigation. J Obstet Gynaecol Can. 2006 Jun. 28(6):540-52. [Medline].

  27. Desilets V, Oligny LL. Fetal and perinatal autopsy in prenatally diagnosed fetal abnormalities with normal karyotype. J Obstet Gynaecol Can. 2011 Oct. 33(10):1047-57. [Medline].

  28. Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. Am J Obstet Gynecol. 1998 Oct. 179(4):884-9. [Medline].

  29. Anand A, Gray ES, Brown T, et al. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987 Jan 22. 316(4):183-6. [Medline].

  30. Andres RL, Brace RA. The development of hydrops fetalis in the ovine fetus after lymphatic ligation or lymphatic excision. Am J Obstet Gynecol. 1990 May. 162(5):1331-4. [Medline].

  31. Aubard Y, Derouineau I, Aubard V, et al. Primary fetal hydrothorax: A literature review and proposed antenatal clinical strategy. Fetal Diagn Ther. 1998 Nov-Dec. 13(6):325-33. [Medline].

  32. Azancot-Benisty A, Areias JC, Oberhansli I, et al. European Study on Maternal and Fetal Management of Fetal Supraventricular Tachyarrhythmia: Proposed Protocol for an International Project. J Matern Fetal Investig. 1998 Jun. 8(2):92-7. [Medline].

  33. Bajoria R, Sullivan M, Fisk NM. Endothelin concentrations in monochorionic twins with severe twin-twin transfusion syndrome. Hum Reprod. 1999 Jun. 14(6):1614-8. [Medline]. [Full Text].

  34. Barron SD, Pass RF. Infectious causes of hydrops fetalis. Semin Perinatol. 1995 Dec. 19(6):493-501. [Medline].

  35. Bejar R, Vigliocco G, Gramajo H, et al. Antenatal origin of neurologic damage in newborn infants. II. Multiple gestations. Am J Obstet Gynecol. 1990 May. 162(5):1230-6. [Medline].

  36. Blickstein I. The twin-twin transfusion syndrome. Obstet Gynecol. 1990 Oct. 76(4):714-22. [Medline].

  37. Bond SJ, Harrison MR, Schmidt KG, et al. Death due to high-output cardiac failure in fetal sacrococcygeal teratoma. J Pediatr Surg. 1990 Dec. 25(12):1287-91. [Medline].

  38. Brace RA. Effects of outflow pressure on fetal lymph flow. Am J Obstet Gynecol. 1989 Feb. 160(2):494-7. [Medline].

  39. Brans YW, Milstead RR, Bailey PE, Cassady G. Blood-volume estimates in Coombs-test-positive infants. N Engl J Med. 1974 Jun 27. 290(26):1450-2. [Medline].

  40. Carlson DE, Platt LD, Medearis AL, Horenstein J. Prognostic indicators of the resolution of nonimmune hydrops fetalis and survival of the fetus. Am J Obstet Gynecol. 1990 Dec. 163(6 Pt 1):1785-7. [Medline].

  41. Cowan RH, Waldo AL, Harris HB, et al. Neonatal paroxysmal supraventricular tachycardia with hydrops. Pediatrics. 1975 Mar. 55(3):428-30. [Medline].

  42. Daniel SJ, Cassady G. Non-immunologic hydrops fetalis associated with a large hemangioendothelioma. Pediatrics. 1968 Nov. 42(5):828-33. [Medline].

  43. De Groot CJ, Oepkes D, Egberts J, Kanhai HH. Evidence of endothelium involvement in the pathophysiology of hydrops fetalis?. Early Hum Dev. 2000 Mar. 57(3):205-9. [Medline].

  44. Dieck D, Schild RL, Hansmann M, Eis-Hubinger AM. Prenatal diagnosis of congenital parvovirus B19 infection: value of serological and PCR techniques in maternal and fetal serum. Prenat Diagn. 1999 Dec. 19(12):1119-23. [Medline].

  45. Driscoll SG. Hydrops fetalis. N Engl J Med. 1966 Dec 22. 275(25):1432-4. [Medline].

  46. Dumez Y, Mandelbrot L, Radunovic N, et al. Prenatal management of congenital cystic adenomatoid malformation of the lung. J Pediatr Surg. 1993 Jan. 28(1):36-41. [Medline].

  47. Faber JJ, Anderson DF. Angiotensin mediated interaction of fetal kidney and placenta in the control of fetal arterial pressure and its role in hydrops fetalis. Placenta. 1997 May. 18(4):313-26. [Medline].

  48. Gembruch U, Knopfle G, Chatterjee M, et al. First-trimester diagnosis of fetal congenital heart disease by transvaginal two-dimensional and Doppler echocardiography. Obstet Gynecol. 1990 Mar. 75(3 Pt 2):496-8. [Medline].

  49. Gest AL, Bair DK, Vander Straten MC. The effect of outflow pressure upon thoracic duct lymph flow rate in fetal sheep. Pediatr Res. 1992 Nov. 32(5):585-8. [Medline].

  50. Gest AL, Hansen TN, Moise AA, Hartley CJ. Atrial tachycardia causes hydrops in fetal lambs. Am J Physiol. 1990 Apr. 258(4 Pt 2):H1159-63. [Medline].

  51. Gest AL, Martin CG, Moise AA, Hansen TN. Reversal of venous blood flow with atrial tachycardia and hydrops in fetal sheep. Pediatr Res. 1990 Sep. 28(3):223-6. [Medline].

  52. Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv. 1997 Jun. 52(6):372-80. [Medline].

  53. Gudmundsson S, Huhta JC, Wood DC, et al. Venous Doppler ultrasonography in the fetus with nonimmune hydrops. Am J Obstet Gynecol. 1991 Jan. 164(1 Pt 1):33-7. [Medline].

  54. Haak MC, Oosterhof H, Mouw RJ. Pathophysiology and treatment of fetal anemia due to placental chorioangioma. Ultrasound Obstet Gynecol. 1999 Jul. 14(1):68-70. [Medline].

  55. Hagay Z, Reece A, Roberts A, Hobbins JC. Isolated fetal pleural effusion: a prenatal management dilemma. Obstet Gynecol. 1993 Jan. 81(1):147-52. [Medline].

  56. Haverkamp F, Noeker M, Gerresheim G, Fahnenstich H. Good prognosis for psychomotor development in survivors with nonimmune hydrops fetalis. Br J Obstet Gynaecol. 2000 Feb. 107(2):282-4. [Medline].

  57. Hirata GI, Masaki DI, O'Toole M, Medearis AL, Platt LD. Color flow mapping and Doppler velocimetry in the diagnosis and management of a placental chorioangioma associated with nonimmune fetal hydrops. Obstet Gynecol. 1993 May. 81(5 ( Pt 2)):850-2. [Medline].

  58. Khouzami AN, Kickler TS, Callan NA, et al. Devastating sequelae of alloimmune thrombocytopenia: an entity that deserves more attention. J Matern Fetal Med. 1996 May-Jun. 5(3):137-41. [Medline].

  59. Kirshon B, Moise KJ Jr, Mari G, et al. In utero resolution of hydrops fetalis following the death of one twin in twin-twin transfusion. Am J Perinatol. 1990 Apr. 7(2):107-9. [Medline].

  60. Knilans TK. Cardiac abnormalities associated with hydrops fetalis. Semin Perinatol. 1995 Dec. 19(6):483-92. [Medline].

  61. Liddle AD, Anderson DR, Mishra PK. Intrapericardial teratoma presenting in fetal life: intrauterine diagnosis and neonatal management. Congenit Heart Dis. 2008 Nov-Dec. 3(6):449-51. [Medline].

  62. Mahone PR, Sherer DM, Abramowicz JS, Woods JR Jr. Twin-twin transfusion syndrome: rapid development of severe hydrops of the donor following selective feticide of the hydropic recipient. Am J Obstet Gynecol. 1993 Jul. 169(1):166-8. [Medline].

  63. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998 Feb. 105(2):174-8. [Medline].

  64. Moise AA, Gest AL, Weickmann PH, McMicken HW. Reduction in plasma protein does not affect body water content in fetal sheep. Pediatr Res. 1991 Jun. 29(6):623-6. [Medline].

  65. Moise KJ Jr, Carpenter RJ Jr, Hesketh DE. Do abnormal Starling forces cause fetal hydrops in red blood cell alloimmunization?. Am J Obstet Gynecol. 1992 Oct. 167(4 Pt 1):907-12. [Medline].

  66. Moya FR, Grannum PA, Riddick L, et al. Atrial natriuretic factor in hydrops fetalis caused by Rh isoimmunisation. Arch Dis Child. 1990 Jul. 65(7 Spec No):683-6. [Medline].

  67. Moya FR, Grannum PA, Widness JA, et al. Erythropoietin in human fetuses with immune hemolytic anemia and hydrops fetalis. Obstet Gynecol. 1993 Sep. 82(3):353-8. [Medline].

  68. Muller-Hansen I, Hackeloer BJ, Kattner E. [Pre- and postnatal diagnosis and treatment of hydrops fetalis--an interdisciplinary problem]. Z Geburtshilfe Neonatol. 1998 Jan-Feb. 202(1):2-9. [Medline].

  69. Murphy JJ, Blair GK, Fraser GC. Coagulopathy associated with large sacrococcygeal teratomas. J Pediatr Surg. 1992 Oct. 27(10):1308-10. [Medline].

  70. Nimrod C, Davies D, Harder J. Ultrasound evaluation of tachycardia-induced hydrops in the fetal lamb. Am J Obstet Gynecol. 1987 Sep. 157(3):655-9. [Medline].

  71. Nimrod C, Keane P, Harder J, et al. Atrial natriuretic peptide production in association with nonimmune fetal hydrops. Am J Obstet Gynecol. 1988 Sep. 159(3):625-8. [Medline].

  72. O-Prasertsawat P, Suthutvoravut S, Chaturachinda K. Hydrops fetalis due to Bart hemoglobinopathy at Ramathibodi Hospital (1978-1987): a 10-year review. J Med Assoc Thai. 1990 Feb. 73 Suppl 1:65-8. [Medline].

  73. Owen J, Colvin EV, Davis RO. Fetal death after successful conversion of fetal supraventricular tachycardia with digoxin and verapamil. Am J Obstet Gynecol. 1988 May. 158(5):1169-70. [Medline].

  74. Paladini D, Chita SK, Allan LD. Prenatal measurement of cardiothoracic ratio in evaluation of heart disease. Arch Dis Child. 1990 Jan. 65(1 Spec No):20-3. [Medline].

  75. Phibbs RH, Johnson P, Tooley WH. Cardiorespiratory status of erythroblastotic newborn infants. II. Blood volume, hematocrit, and serum albumin concentration in relation to hydrops fetalis. Pediatrics. 1974 Jan. 53(1):13-23. [Medline].

  76. Potter EL. Universal edema of the fetus unassociated with erythroblastosis. Am J Obstet Gynecol. 1943. 46:130-134.

  77. Revillon Y, Jan D, Plattner V, et al. Congenital cystic adenomatoid malformation of the lung: prenatal management and prognosis. J Pediatr Surg. 1993 Aug. 28(8):1009-11. [Medline].

  78. Rice HE, Estes JM, Hedrick MH, et al. Congenital cystic adenomatoid malformation: a sheep model of fetal hydrops. J Pediatr Surg. 1994 May. 29(5):692-6. [Medline].

  79. Rodis JF, Borgida AF, Wilson M, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol. 1998 Oct. 179(4):985-8. [Medline].

  80. Ross BA. Congenital complete atrioventricular block. Pediatr Clin North Am. 1990 Feb. 37(1):69-78. [Medline].

  81. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum. 1999 Nov. 42(11):2335-45. [Medline].

  82. Sharma RS, Yu V, Walters WA. Haemoglobin Bart's hydrops fetalis syndrome in an infant of Greek origin and prenatal diagnosis of alpha-thalassaemia. Med J Aust. 1979 Oct 20. 2(8):404, 433-4. [Medline].

  83. Shimokawa H, Sumioki H, Miyamoto S, et al. Is human atrial natriuretic peptide in fetal blood useful as a parameter to detect the decompensated state of the fetal heart?. J Perinat Med. 1988. 16(5-6):485-6. [Medline].

  84. Shiraishi S, Kinukawa N, Nakano H, Sueishi K. Immunohistochemical distribution of vascular endothelial growth factor in the human placenta associated with hydrops fetalis. Pediatr Pathol Lab Med. 1997 Jan-Feb. 17(1):65-81. [Medline].

  85. Silberbach M, Anderson DF, Reller MD. Effect of atrial natriuretic peptide on vascular permeation in the ovine fetus. Pediatr Res. 1994 May. 35(5):555-9. [Medline].

  86. Silberbach M, Woods LL, Hohimer AR, et al. Role of endogenous atrial natriuretic peptide in chronic anemia in the ovine fetus: effects of a non-peptide antagonist for atrial natriuretic peptide receptor. Pediatr Res. 1995 Nov. 38(5):722-8. [Medline].

  87. Silverman NH, Schmidt KG. Ventricular volume overload in the human fetus: observations from fetal echocardiography. J Am Soc Echocardiogr. 1990 Jan-Feb. 3(1):20-9. [Medline].

  88. Simpson JM, Sharland GK. Fetal tachycardias: management and outcome of 127 consecutive cases. Heart. 1998 Jun. 79(6):576-81. [Medline]. [Full Text].

  89. Strasburger JF, Huhta JC, Carpenter RJ Jr, et al. Doppler echocardiography in the diagnosis and management of persistent fetal arrhythmias. J Am Coll Cardiol. 1986 Jun. 7(6):1386-91. [Medline].

  90. Sun CC, Panny S, Combs J, Gutberlett R. Hydrops fetalis associated with Gaucher disease. Pathol Res Pract. 1984 Sep. 179(1):101-4. [Medline].

  91. Tannirandorn Y, Fisk NM, Shah V, et al. Plasma renin activity in fetal disease. J Perinat Med. 1990. 18(3):229-31. [Medline].

  92. Thorpe-Beeston JG, Nicolaides KH. Cystic adenomatoid malformation of the lung: prenatal diagnosis and outcome. Prenat Diagn. 1994 Aug. 14(8):677-88. [Medline].

  93. Tongsong T, Wanapirak C, Piyamongkol W, Sudasana J. Prenatal sonographic features of sacrococcygeal teratoma. Int J Gynaecol Obstet. 1999 Nov. 67(2):95-101. [Medline].

  94. Ulm B, Svolba G, Ulm MR, et al. Male fetuses are particularly affected by maternal alloimmunization to D antigen. Transfusion. 1999 Feb. 39(2):169-73. [Medline].

  95. van der Straten MC, Gest AL. Hemolytic anemia without an increased central venous pressure does not cause hydrops in fetal sheep (Abstract). Clin Res. 1993. 41:771A.

  96. van Engelen AD, Weijtens O, Brenner JI, et al. Management outcome and follow-up of fetal tachycardia. J Am Coll Cardiol. 1994 Nov 1. 24(5):1371-5. [Medline].

  97. Venkat-Raman N, Sebire NJ, Murphy KW. Recurrent fetal hydrops due to mucopolysaccharidoses type VII. Fetal Diagn Ther. 2006. 21(3):250-4. [Medline].

  98. Ville Y, Proudler A, Kuhn P, Nicolaides KH. Aldosterone concentration in normal, growth-retarded, anemic, and hydropic fetuses. Obstet Gynecol. 1994 Oct. 84(4):511-4. [Medline].

  99. Watson J, Campbell S. Antenatal evaluation and management in nonimmune hydrops fetalis. Obstet Gynecol. 1986 Apr. 67(4):589-93. [Medline].

  100. Weiner CP, Pelzer GD, Heilskov J, et al. The effect of intravascular transfusion on umbilical venous pressure in anemic fetuses with and without hydrops. Am J Obstet Gynecol. 1989 Dec. 161(6 Pt 1):1498-501. [Medline].

  101. Weiner CP, Robillard JE. Atrial natriuretic factor, digoxin-like immunoreactive substance, norepinephrine, epinephrine, and plasma renin activity in human fetuses and their alteration by fetal disease. Am J Obstet Gynecol. 1988 Dec. 159(6):1353-60. [Medline].

  102. Whitecar PW, Moise KJ Jr. Sonographic methods to detect fetal anemia in red blood cell alloimmunization. Obstet Gynecol Surv. 2000 Apr. 55(4):240-50. [Medline].

  103. Williams IA, Kleinman CS. Is hydrops fetalis a manifestation of fetal pulmonary edema caused by impaired lymphatic drainage?. Ultrasound Obstet Gynecol. 2008 Jan. 31(1):96-9. [Medline].

  104. Wolf RB, Moore TR. Amniotic fluid and nonimmune hydrops fetalis. Fanaroff and Martin's Neonatal-Perinatal Medicine. 8th ed. 2006. 409-28.

  105. Yaegashi N, Niinuma T, Chisaka H, et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect. 1998 Jul. 37(1):28-35. [Medline].

  106. Yamada A, Kasugai M, Ohno Y, et al. Antenatal diagnosis of twin-twin transfusion syndrome by Doppler ultrasound. Obstet Gynecol. 1991 Dec. 78(6):1058-61. [Medline].

  107. Yamada H, Kato EH, Furuta I, et al. Hematopoietic cytokine levels and in vitro colony formation assay in fetal anemia. Semin Thromb Hemost. 1998. 24(5):485-90. [Medline].

  108. Zankl A, Osterheld MC, Vial Y, Beurret N, et al. Right-sided diaphragmatic eventration: a rare cause of non-immune hydrops fetalis. Neonatology. 2007. 92(1):14-8. [Medline].

Chest radiograph revealing pleural effusion with bilateral chest tubes and severe edema.
Chest and abdomen radiograph revealing severe edema and ascites.
Chest and abdomen radiograph revealing severe edema, pleural effusion, and bilateral chest tubes. Umbilical artery catheter, umbilical vein catheter, and endotracheal tube in place.
Medscape Consult